ELTP ELITE PHARMACEUTICALS INC /NV/
Pharmaceutical Preparations · OTC · SEC CIK 1053369 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.8%
TTM net income YoY333.0%
TTM EPS YoY50.0%
Revenue 3-yr CAGR52.2%
Net income 3-yr CAGR50.1%
Margins
Gross margin43.7%
Operating margin25.3%
Net margin41.6%
FCF margin6.0%
EBITDA margin26.1%
Returns
ROE65.6%
ROA46.1%
ROIC (approx.)52.7%
Asset turnover1.11x
Leverage & solvency
Liabilities / assets15.3%
Debt / equity0.00x
Current ratio6.65x
Interest coverage338.18x
Cash quality & payout
Operating cash flow / net income0.18x
Accruals ratio37.8%
Payout ratio—
Capex / revenue1.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | $148.87M | $84.04M |
| Cost of revenue | $73.85M | $43.96M |
| Gross profit | $75.02M | $40.09M |
| R&D expense | $5.74M | $7.96M |
| SG&A expense | $17.60M | $9.00M |
| Operating income | $49.11M | $19.60M |
| Interest expense | $111,361 | $128,234 |
| Pretax income | $56.81M | -$52,140 |
| Income tax | $11.94M | $4.26M |
| Net income | $44.87M | -$4.31M |
| EBITDA | $50.18M | $20.83M |
| EPS (basic) | 0.04 | 0.00 |
| EPS (diluted) | 0.03 | 0.00 |
| Weighted avg. shares (diluted) | 1.14B | 1.07B |
| Balance sheet | ||
| Cash & equivalents | $29.80M | $11.77M |
| Receivables | $59.72M | $29.21M |
| Inventory | $21.26M | $16.24M |
| Current assets | $112.11M | $57.74M |
| PP&E, net | $10.18M | $10.33M |
| Intangibles | $4.79M | $5.64M |
| Total assets | $138.29M | $96.39M |
| Current liabilities | $17.39M | $11.84M |
| Total liabilities | $39.41M | $42.87M |
| Shareholders' equity | $98.88M | $53.52M |
| Shares outstanding | 1.08B | 1.07B |
| Cash flow statement | ||
| Operating cash flow | $23.75M | $7.46M |
| Capital expenditure | $925,626 | $1.63M |
| Free cash flow | $22.82M | $5.83M |
| Investing cash flow | -$925,626 | -$2.40M |
| Financing cash flow | -$4.32M | -$825,740 |
| Depreciation & amortization | $1.07M | $1.23M |
| Stock-based compensation | $176,507 | $227,565 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.